A verification study to evaluate the safety of excessive consumption of the test food

A verification study to evaluate the safety of excessive consumption of the test food: an open-label study - A verification study to evaluate the safety of excessive consumption of the test food

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000061976

Enrollment

Registered

2026-06-19

Start date

2026-06-19

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese

Interventions

Duration: Four weeks Test product: Mindrevive (R) Administration: Take 10 tablets per day with water without chewing. *If a dose is missed, it should be consumed as soon as remembered. The daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Adults 4. Healthy individuals

Exclusion criteria

Exclusion criteria: 1. Individuals who are receiving treatment for or have a history of malignant tumors, heart failure, or myocardial infarction 2. Individuals who have an implanted pacemaker or implantable cardioverter defibrillator 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who consume Foods for Specified Health Uses or Foods with Functional Claims 5. Individuals who are taking or using medications (including herbal medicines) or supplements 6. Individuals who are allergic to medications or foods related to the test product 7. Individuals who are pregnant, lactating, or planning pregnancy during this study 8. Individuals who have participated in other clinical studies within 28 days before informed consent, or plan to participate in another study during this study 9. Individuals who are deemed unsuitable for participation in this study by the principal investigator

Design outcomes

Primary

Measure	Time frame
1. Individuals who experienced adverse events	—

Secondary

Measure	Time frame
1. Individuals whose urinalysis and peripheral blood test values were within the reference range at screening but became outside the reference range after intervention 2. Physical measurements, urinalysis, and peripheral blood test	—

Countries

Japan

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026